Voglibose
![]() | This article needs additional citations for verification. (September 2009) |
![]() | |
Clinical data | |
---|---|
AHFS/Drugs.com | International Drug Names |
ATC code | |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C10H21NO7 |
Molar mass | 267.278 g·mol−1 |
3D model (JSmol) | |
| |
| |
Voglibose (INN and USAN, trade name Voglib, marketed by Mascot Health Series) is an alpha-glucosidase inhibitor used for lowering postprandial blood glucose levels in people with diabetes mellitus.[1] Voglibose delays the absorption of glucose thereby reducing the risk of macrovascular complications. Voglibose is a research product of Takeda Pharmaceutical Company, Japan's largest pharmaceutical company. Vogilbose was discovered in 1981, and was first launched in Japan in 1994,[2] under the trade name BASEN, to improve postprandial hyperglycemia in diabetes mellitus.[3]
Postprandial hyperglycemia (PPHG) is primarily due to first phase insulin secretion. Alpha glucosidase inhibitors delay glucose absorption at the intestine level and thereby prevent sudden surge of glucose after a meal.[2]
There are three major drugs which belong to this class, acarbose, miglitol and voglibose,[2] of which voglibose is the newest.
References[]
- ^ Chen X, Zheng Y, Shen Y (2006). "Voglibose (Basen, AO-128), one of the most important alpha-glucosidase inhibitors". Current Medicinal Chemistry. 13 (1): 109–16. doi:10.2174/092986706789803035. PMID 16457643.
- ^ a b c Dabhi AS, Bhatt NR, Shah MJ (December 2013). "Voglibose: an alpha glucosidase inhibitor". Journal of Clinical and Diagnostic Research. 7 (12): 3023–7. doi:10.7860/JCDR/2013/6373.3838. PMC 3919386. PMID 24551718.
- ^ "Voglibose". AdisInsight. Springer Nature Switzerland AG.
Further reading[]
- Greenstein B (2004). Clinical Pharmacology for nurses (17th ed.). Elsevier Limited, Churchill Livingstone.
- Andrew L. Wilson (1997). Ila V. Mehra (ed.). Managing the Patient with Type II Diabetes. Aspen Publishers. pp. 62–63. ISBN 978-0-8342-1018-9.
{{cite book}}
: CS1 maint: uses authors parameter (link)
- Alpha-glucosidase inhibitors
- Amino sugars